PT - JOURNAL ARTICLE AU - Carolina Lucas AU - Patrick Wong AU - Jon Klein AU - Tiago B.R. Castro AU - Julio Silva AU - Maria Sundaram AU - Mallory K. Ellingson AU - Tianyang Mao AU - Ji Eun Oh AU - Benjamin Israelow AU - Maria Tokuyama AU - Peiwen Lu AU - Arvind Venkataraman AU - Annsea Park AU - Subhasis Mohanty AU - Haowei Wang AU - Anne L. Wyllie AU - Chantal B.F. Vogels AU - Rebecca Earnest AU - Sarah Lapidus AU - Isabel M. Ott AU - Adam J. Moore AU - M. Catherine Muenker AU - John B. Fournier AU - Melissa Campbell AU - Camila D. Odio AU - Arnau Casanovas-Massana AU - Yale IMPACT Team AU - Roy Herbst AU - Albert C. Shaw AU - Ruslan Medzhitov AU - Wade L. Schulz AU - Nathan D. Grubaugh AU - Charles Dela Cruz AU - Shelli Farhadian AU - Albert I. Ko AU - Saad B. Omer AU - Akiko Iwasaki TI - Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients AID - 10.1101/2020.06.23.20138289 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.23.20138289 4099 - http://medrxiv.org/content/early/2020/06/25/2020.06.23.20138289.short 4100 - http://medrxiv.org/content/early/2020/06/25/2020.06.23.20138289.full AB - Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19)1-4. Yet, longitudinal immunological correlates of disease outcome remain unclear. Here, we serially analysed immune responses in 113 COVID-19 patients with moderate (non-ICU) and severe (ICU) disease. Immune profiling revealed an overall increase in innate cell lineages with a concomitant reduction in T cell number. We identify an association between early, elevated cytokines and worse disease outcomes. Following an early increase in cytokines, COVID-19 patients with moderate disease displayed a progressive reduction in type-1 (antiviral) and type-3 (antifungal) responses. In contrast, patients with severe disease maintained these elevated responses throughout the course of disease. Moreover, severe disease was accompanied by an increase in multiple type 2 (anti-helminths) effectors including, IL-5, IL-13, IgE and eosinophils. Unsupervised clustering analysis of plasma and peripheral blood leukocyte data identified 4 immune signatures, representing (A) growth factors, (B) type-2/3 cytokines, (C) mixed type-1/2/3 cytokines, and (D) chemokines that correlated with three distinct disease trajectories of patients. The immune profile of patients who recovered with moderate disease was enriched in tissue reparative growth factor signature (A), while the profile for those with worsened disease trajectory had elevated levels of all four signatures. Thus, we identified development of a maladapted immune response profile associated with severe COVID-19 outcome and early immune signatures that correlate with divergent disease trajectories.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Womens Health Research at Yale Pilot Project Program (AI, AR), Fast Grant from Emergent Ventures at the Mercatus Center, Mathers Foundation, and the Ludwig Family Foundation, the Department of Internal Medicine at the Yale School of Medicine, Yale School of Public Health and Beatrice Kleinberg Neuwirth Fund. A.I. is an Investigator of the Howard Hughes Medical Institute. C.L. is a Pew Latin American Fellow. P.Y is supported by Gruber Foundation and the NSF. B.I is supported by NIAID 2T32AI007517-16. CBFV is supported by NOW Rubicon 019.181EN.004.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, Protocol ID. 2000027690). Informed consents were obtained from all enrolled patients and healthcare workers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study will be made openly available in public repositories.